Do FADS1 variants and TNF rs1800629 shape inflammatory potential?

Genetic variations in fatty acid metabolism and cytokine promoter regions interactively shape an individual's systemic inflammatory potential.

Biochemical and genetic mechanisms

• FADS1 and Fatty Acid Conversion: The FADS1 gene encodes delta-5 desaturase (D5D), which converts dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA). Variants like rs174537 and rs174547 alter this conversion. The rs174537 variant accounts for 18% to 19% of the variance in plasma AA levels, with minor T-allele carriers showing reduced D5D activity.
• Synthesis Capacity: In vivo tracer studies show that homozygous minor CC carriers of rs174547 possess only 37% of the AA synthesis capacity from dietary precursors compared to major TT homozygotes.
• Eicosanoid Production: Increased conversion of linoleic acid to AA expands the substrate pool available for synthesizing downstream arachidonic acid-derived eicosanoids. These lipid mediators act as pro-inflammatory signals that upregulate and modify downstream cytokine expression.

Cytokine signaling under stress

• TNF Transcription: The TNF rs1800629 (G-308A) promoter variant directly regulates cytokine output. Carrying the minor A-allele alters transcription factor binding kinetics, leading to a 2- to 3-fold increase in TNF-alpha transcriptional activity compared to the G-allele.
• Context-Dependent Activation: This genetic susceptibility is highly conditional. Increased transcription and elevated downstream biomarkers, such as C-reactive protein (CRP), are selectively revealed under active inflammatory pressure—including cellular exposure to lipopolysaccharide (LPS), phorbol myristate acetate (PMA), or interleukin-1 alpha (IL-1α).

Bottom line

• FADS1 variants dictate the systemic pool of arachidonic acid and downstream pro-inflammatory eicosanoids, while the TNF rs1800629 A-allele acts as a genetic amplifier of cytokine signaling under active inflammatory pressure.